Skip to main content

Together we are beating cancer

Donate now

Cancer News

The latest news, analysis and opinion from Cancer Research UK

Immunotherapy

Showing 12 out of 206 results
An illustration of a T cell

With help from a new Nobel Laureate, Cancer Grand Challenges team MATCHMAKERS are developing AI models that can identify the immune cells best equipped to fight different cancers. That should make it possible to improve immunotherapies and match patients with the treatments best suited to them as individuals. With help from a new Nobel Laureate, Cancer Grand Challenges team MATCHMAKERS are developing AI models that can identify the immune cells best equipped to fight different cancers. That should make it possible to improve immunotherapies and match patients with the treatments best suited to them as individuals.

by Jacob Smith | Analysis | 31 October 2024

31 October 2024

Brain scans

Stand Up To Cancer are giving two international teams each a further £3.75m to reduce the side effects of radiotherapy and make immunotherapies work for more young patients. Stand Up To Cancer are giving two international teams each a further £3.75m to reduce the side effects of radiotherapy and make immunotherapies work for more young patients.

by Tim Gunn | Analysis | 7 August 2024

7 August 2024

Endometrial adenocarcinoma cells viewed under the microscope

Dostarlimab (also called Jemperli) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat some types of advanced or recurrent womb cancer Dostarlimab (also called Jemperli) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat some types of advanced or recurrent womb cancer

by Jacob Smith | News | 8 March 2024

8 March 2024

Cells with nuclei in blue and mitochondria (energy factories) in green.

Our researchers have found mutations that make cancers much more likely to respond to immunotherapy. It's a chance to make breakthrough treatments work for many more people. Our researchers have found mutations that make cancers much more likely to respond to immunotherapy. It's a chance to make breakthrough treatments work for many more people.

by Tim Gunn | Analysis | 31 January 2024

31 January 2024

Lung cancer cell

Immunotherapy is a new type of treatment causing a buzz in the medical community. But what makes it so exciting? Immunotherapy is a new type of treatment causing a buzz in the medical community. But what makes it so exciting?

by Cancer Research UK | Philanthropy and partnerships | 25 January 2024

25 January 2024

Two researchers smiling as they work together in a lab

2023 has been a big year for Cancer Research UK, and there's been a lot to celebrate. So, to end the year, we want to highlight just a few of our most exciting research stories of 2023. 2023 has been a big year for Cancer Research UK, and there's been a lot to celebrate. So, to end the year, we want to highlight just a few of our most exciting research stories of 2023.

by Jacob Smith | In depth | 18 December 2023

18 December 2023

A magnified image of squamous cell carcinoma, the most common type of cervical cancer

The immunotherapy pembrolizumab may help some people with incurable cervical cancer live longer. It's now an approved treatment for them in England and Scotland. The immunotherapy pembrolizumab may help some people with incurable cervical cancer live longer. It's now an approved treatment for them in England and Scotland.

by Tim Gunn | News | 16 May 2023

16 May 2023

A scientist handling patient samples at an experimental cancer medicine centre.

We're helping treble funding for paediatric Experimental Cancer Medicine Centres, paving the way to more effective and less toxic treatments for children and young people. We're helping treble funding for paediatric Experimental Cancer Medicine Centres, paving the way to more effective and less toxic treatments for children and young people.

by Tim Gunn | In depth | 3 April 2023

3 April 2023

Breast cancer cell seen through a scanning electron microscope

The "potentially life-saving" immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales. The "potentially life-saving" immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales.

by Tim Gunn | News | 14 November 2022

14 November 2022

T cell

Researchers in Southampton have found a way to improve the effectiveness of immunotherapy in cancers that are resistant by repurposing existing drugs Researchers in Southampton have found a way to improve the effectiveness of immunotherapy in cancers that are resistant by repurposing existing drugs

by Jacob Smith | Analysis | 11 November 2022

11 November 2022